Golcadomide
- Generic Name
- Golcadomide
- Drug Type
- Small Molecule
- Chemical Formula
- C28H30FN5O5
- CAS Number
- 2379572-34-4
- Unique Ingredient Identifier
- 29HLR8Z5BR
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
• DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
• Several major pharmaceutical companies including BeiGene, Celgene, Hoffmann-La Roche, and Allogene Therapeutics have initiated pivotal late-stage clinical trials for novel B-cell lymphoma treatments in March 2025.
• Emerging therapies include CAR-T cell approaches, bispecific antibodies, and novel targeted agents, with many incorporating dual-targeting mechanisms to overcome resistance seen with single-target therapies.
Follicular Lymphoma Pipeline Shows Promise with Over 55 Therapies in Development
• The follicular lymphoma treatment landscape is evolving, with over 55 therapies in development by more than 50 active pharmaceutical companies.
• Key players like Incyte, AstraZeneca, and Johnson & Johnson are evaluating novel drugs, including CAR-T therapies and targeted agents, to improve patient outcomes.
• Tafasitamab is expected to have a supplemental Biologics License Application filed in August 2024 for patients who have failed prior therapies.
• Emerging therapies in the pipeline include TQ-B3525, NKTR-255, and Zilovertamab vedotin, targeting various mechanisms to combat follicular lymphoma.
T-Cell Lymphoma Pipeline Shows Promise with Novel Therapies and Regulatory Support
• The T-Cell Lymphoma drug pipeline is advancing with key players like Eisai, Takeda, and Rhizen Pharmaceuticals developing innovative therapies.
• Immunomodulatory drugs such as Lenalidomide and monoclonal antibodies like Isatuximab SAR650984 are in clinical trials, showing potential in improving patient outcomes.
• Regulatory support, including fast-track designations, is expediting the development and approval of novel T-Cell Lymphoma treatments.
• CAR T-cell therapy, such as lisocabtagene maraleucel (Breyanzi), has been approved for certain lymphomas, offering new options for patients who have not responded to other treatments.
T-Cell Malignancy Pipeline Shows Promise with Novel Therapies and Approvals
• The T-cell malignancies market is experiencing growth driven by increased incidence, treatment advancements, and strategic biopharma partnerships.
• Several companies, including Corvus Pharmaceuticals and Kymera Therapeutics, are advancing novel therapies through clinical trials, targeting unmet needs in T-cell lymphomas.
• Regulatory milestones, such as FDA Fast Track Designation for soquelitinib and EMA Orphan Drug Designation for SLS009, are accelerating the development of new treatments.
• Research and development efforts, highlighted by presentations at major conferences like EHA, are yielding promising clinical data for drugs like KT-333.
Bristol-Myers Squibb's MYK-224 for Hypertrophic Cardiomyopathy Projects $41M Revenue by 2035
• Bristol-Myers Squibb is developing MYK-224, an oral myosin-targeting drug for obstructive hypertrophic cardiomyopathy and diastolic heart failure, with projected US revenue of $41 million by 2035.
• The drug's development strategy focuses on addressing significant unmet needs in cardiac conditions, particularly heart failure with preserved ejection fraction (HFpEF).
• BMS demonstrates continued investment in cardiovascular therapeutics despite recent overall revenue decrease of 2.5% in FY2023, maintaining an operating margin of 20.9%.
Golcadomide Plus R-CHOP Shows Promise in Aggressive B-Cell Lymphoma
• Golcadomide combined with R-CHOP demonstrates a manageable safety profile and promising antitumor activity in previously untreated aggressive B-cell lymphoma.
• The 0.4-mg dose of golcadomide with R-CHOP resulted in high complete metabolic response rates, irrespective of cell of origin, in the phase 1b CC-220-DLBCL-001 trial.
• High-risk patients treated with the golcadomide combination showed encouraging 12-month progression-free survival and overall survival rates.
• These findings support the ongoing phase 3 GOLSEEK-1 trial evaluating golcadomide plus R-CHOP versus R-CHOP alone in high-risk large B-cell lymphoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath